title: Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.
authors.affiliation: Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Canada and Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan hirotak@dk9.so-net.ne.jp; Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Anthropology, University of Toronto, Toronto, Canada; Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Institute of Medical Science, University of Toronto, Toronto, Canada; Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto and Institute of Medical Science, University of Toronto and Campbell Family Mental, Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Sadhana
authors.initials: S
authors.lastname: Thiyanavadivel
authors.forename: Gagan
authors.initials: G
authors.lastname: Fervaha
authors.forename: Gary
authors.initials: G
authors.lastname: Remington
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology*; D060825:Cognitive Dysfunction / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents